KEGG   DRUG: VantictumabHelp
Entry
D10410                      Drug                                   

Name
Vantictumab (USAN)
Formula
C6322H9722N1674O1988S46
Exact mass
142371.8264
Mol weight
142459.8511
Sequence
(Heavy chain) EVQLVESGGG LVQPGGSLRL SCAASGFTFS HYTLSWVRQA
PGKGLEWVSV ISGDGSYTYY ADSVKGRFTI SSDNSKNTLY LQMNSLRAED TAVYYCARNF
IKYVFANWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN
SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT CNVDHKPSNT KVDKTVERKC
CVECPPCPAP PVAGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE
VHNAKTKPRE EQFNSTFRVV SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPG
(Light chain) DIELTQPPSV SVAPGQTARI SCSGDNIGSF YVHWYQQKPG
QAPVLVIYDK SNRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQSY ANTLSLVFGG
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK ADSSPVKAGV
ETTTPSKQSN NKYAASSYLS LTPEQWKSHR SYSCQVTHEG STVEKTVAPT ECS
(Dimer; Disulfide bridges: H22-H96, L22-L87, H'22-H'96, L'22-L'87, H132-L212, H'132-L'212, L135-L194, L'135-L'194, H145-H201, H'145-H'201, H220-H'220, H221-H'221, H224-H'224, H227-H'227, H258-H318, H'258-H'318, H364-H422, H'364-H'422; Glycosylation sites (N)
: Asn-H294, Asn-H'294)
  Type
Peptide
Efficacy
Antineoplastic, Anti-Frizzled family receptor 7 antibody
Comment
Monoclonal antibody
Target
FZD7 [HSA:8324] [KO:K02432]
  Pathway
hsa04310  Wnt signaling pathway
hsa05200  Pathways in cancer
Brite
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Signaling molecules
   Wnt signaling
    FZD7
     D10410  Vantictumab (USAN)
BRITE hierarchy
Other DBs
CAS: 1345009-45-1
PubChem: 172232503
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system